Global Health Research
The overarching focus of the work in Dr. Kirkpatrick’s lab and in the Vaccine Testing Center is the concentration on Infectious Diseases of global significance. Our two main areas of interest are vaccine development and infectious disease immunology. We are also interested in characterizing how the human host responds immunologically to clinically important infectious agents and vaccines. The goal of this work is to gain a better understanding of immunologic responses to vaccines as well as natural infection.
Ongoing Vaccine Research Trials
- Immunological Exploration- The Dengue Human Infection Model: Defining Correlates of Protection and Advancing Vaccine Development.
- A Phase I Study of the Safety and Immunogenicity of a 2-dose Regimen of West Nile/Dengue 4-3'∆30 Chimeric Virus Vaccine.
- A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine.
- Exploration of the Biologic Basis for the Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh.
Previous Clinical Research Trials
- Typhoid Fever
- Cryptosporidium infections
- Campylobacter jejuni infections
Fimlaid KA, Lindow JC, Tribble DR, Bunn JY, Maue AC, Kirkpatrick BD. Peripheral CD4+ T Cell Cytokine Responses Following Human Challenge and Re-challenge with Campylobacter jejuni. PLOS ONE 2014; 9 (11) e112513: 1-8
Haque R, Snider C, Ma Jennie, Liu Y, Nayak U, Mychaleckyj J, Korpe P, Mondal D, Kabir M, Alam M, Pallansch M, Kirkpatrick BD, Petri WA. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. Vaccine 2014; 32: 478-482.
Kirkpatrick BD, Lyon CE, Porter CK, Maue AC, Guerry P, Pierce KK, Carmolli MP, Riddle MS, Larsson CJ, Hawk D, Dill EA, Fingar A, Poly F, Hoq F, Tribble DR. Lack of Homologous Protection Against Campylobacter jejuni CG8421 in a Human Challenge Model. Clinical Infectious Diseases. 2013; 57 (8): 1106-1113.
Lindow JC, Durbin AP, Whitehead SS, Pierce KK, Carmolli MP, Kirkpatrick BD. Vaccination of volunteers with low-dose live attenuated dengue viruses leads to distinct immunologic and virologic profiles. Vaccine 2013; 31: 3347-52. PMC3777849
Durbin AP*, Kirkpatrick BD,* Pierce KK, Elwood D, Larsson CJ, Lindow JC, Tibery C, Sabundayo BP, Shaffer D, Talaat KR, Hynes NA, Wanionek K, Carmolli MP, Luke CJ, Murphy BR, Subbarao K, Whitehead SS. A Single Dose of Any Four Different Live Attenuated Tetravalent Dengue Vaccines is Safe and Immunogenic in Flavivirus-naïve Adults: A Randomized, Double Blind Clinical Trial. Journal of Infectious Disease. 2013; 207: 957-65. (*shared first author) PMC3571448
Lindow JC, Fimlaid K, Bunn J, Durbin AP, Whitehead SS, Kirkpatrick BD. Primary Vaccination with Low Dose Live Dengue 1 Virus Generates a Pro-inflammatory, Multifunctional T Cell Response in Humans. PLOS Neglected Tropical Diseases. 2012; 6 (7): e1742. PMC3398956
Last modified January 29 2015 03:56 PM